Can Novo Nordisk's Aggressive Deal-Making Offset Semaglutide Reliance?

Key Takeaways Novo Nordisk will acquire Akero Therapeutics for $4.7B plus a contingent $6 per share payment.The deal gives NVO access to Akero's EFX, a late-stage FGF21 analog for MASH with fibrosis regression data.The acquisition advances NVO's goal to broaden its cardiometabolic portfolio beyond semaglutide therapies.Novo Nordisk (NVO) continues to derive the bulk of its revenue from its blockbuster semaglutide (GLP-1 RA) therapies, Wegovy for obesity and Ozempic for type II diabetes (T2D). Together, the ...